Comparison of pro-inflammatory cytokines of non-healing and healing cutaneous leishmaniasis.
Cutaneous leishmaniasis (CL) heals spontaneously within several weeks or months, but, in rare cases, CL-active lesions last for many years. In this study, we assessed cell-mediated immunity in non-healing CL through the measurement of three pro-inflammatory cytokines: Interferon-γ (IFN-γ), IL-17a and CXCL-11. For this, 32 patients afflicted with healing or non-healing CL were recruited in this study. Peripheral blood mononuclear cells (PBMCs) of every patient were treated with three antigens: purified protein derivative (PPD), soluble Leishmania antigen (SLA) and phytohaemagglutinin (PHA). Cytokine quantification was performed using enzyme-linked immunosorbent assay (ELISA) method. Results of our study showed that neither cytokine produced in the presence of a PPD stimulator (as an irrelevant antigen) significantly differed between the healing and non-healing groups (P-value ≥0.05 for all of them). However, IFN-γ, CXCL-11 and IL-17a levels produced in the presence of PHA or SLA were significantly higher within the healing than in the non-healing group (P-value <0.01 for all of them). It seems that appropriate levels of IFN-γ, as well as IL-17a and CXCL-11, contribute to the control of Leishmania infection.
Department of Pathobiology, Faculty of Veterinary Science, Bu-Ali Sina University, Hamedan, Iran.
M
M
Moafi
Department of Pathobiology, Faculty of Veterinary Science, Bu-Ali Sina University, Hamedan, Iran.
H
H
Rezvan
Acquired Immunodeficiency Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
R
R
Sherkat
Acquired Immunodeficiency Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
R
R
Taleban
Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
A
A
Asilian
Department of Biology, Faculty of Sciences, University of Isfahan, Isfahan, Iran.
S
S
Hamid Zarkesh-Esfahani
Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran.
M A
MA
Nilforoushzadeh
Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
F
F
Jaffary
Department of Biostatistics and Epidemiology, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran.
M
M
Mansourian
Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
F
F
Sokhanvari
Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
N
N
Ansari
D000293:Adolescent; D000328:Adult; D000953:Antigens, Protozoan / Q000276:immunology; D054371:Chemokine CXCL11 / Q000097:blood*; D002648:Child; D003430:Cross-Sectional Studies; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007371:Interferon-gamma / Q000097:blood*; D020381:Interleukin-17 / Q000097:blood*; D007891:Leishmania / Q000276:immunology*; D016773:Leishmaniasis, Cutaneous / Q000097:blood* / Q000276:immunology* / Q000469:parasitology; D008297:Male; D008875:Middle Aged; D010835:Phytohemagglutinins / Q000276:immunology; D014373:Tuberculin / Q000276:immunology; D055815:Young Adult
D000953:Antigens, Protozoan; C515202:CXCL11 protein, human; D054371:Chemokine CXCL11; C508717:IL17A protein, human; D020381:Interleukin-17; D010835:Phytohemagglutinins; D014373:Tuberculin; D007371:Interferon-gamma